[ad_1]
According to the study’s results, a therapeutic dose of heparin did not appear to have an impact on the “primary outcome” – a combination of death, need for ventilation or admission to intensive care.
However, doses of the drug did appear to reduce the risk of death in about 78 percent of moderately ill patients.
The findings were published this week in the British Medical Journal.
Dr Peter Juni, Director of the Applied Health Research Centre at St. Michael’s and co-lead of the study, said: “Our study confirms therapeutic heparin is beneficial in patients who are on the ward with COVID-19, but other studies suggest it could be harmful for patients who are in critical care.”
[ad_2]
